372 related articles for article (PubMed ID: 23382019)
1. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma.
Moussa E; Zamzam M; Kamel A; Salah Z; Attia I; Gaber L; Soliman R; Ezzat S
J Egypt Natl Canc Inst; 2017 Mar; 29(1):53-56. PubMed ID: 28258912
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.
Watts RG; George M; Johnson WH
Cancer; 2012 Apr; 118(7):1919-24. PubMed ID: 21882180
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors.
Andolina JR; Dilley K
J Pediatr Hematol Oncol; 2010 Jul; 32(5):411-5. PubMed ID: 20495481
[TBL] [Abstract][Full Text] [Related]
6. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
7. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).
Longhi A; Ferrari S; Tamburini A; Luksch R; Fagioli F; Bacci G; Ferrari C
Cancer; 2012 Oct; 118(20):5050-9. PubMed ID: 22415578
[TBL] [Abstract][Full Text] [Related]
8. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
9. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
10. The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity.
Chia PL; Chiang K; Snyder R; Dowling A
J Oncol Pharm Pract; 2018 Jun; 24(4):264-271. PubMed ID: 29284360
[TBL] [Abstract][Full Text] [Related]
11. Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients.
Kakadekar AP; Sandor GG; Fryer C; Chan KW; Rogers PC; Pritchard S; Popov R
Med Pediatr Oncol; 1997 Jan; 28(1):22-6. PubMed ID: 8950332
[TBL] [Abstract][Full Text] [Related]
12. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
[TBL] [Abstract][Full Text] [Related]
13. Multicentre analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH.
Marx M; Langer T; Graf N; Hausdorf G; Stöhr W; Ludwig R; Beck JD
Med Pediatr Oncol; 2002 Jul; 39(1):18-24. PubMed ID: 12116074
[TBL] [Abstract][Full Text] [Related]
14. Subclinical anthracycline cardiotoxicity in patients with acute promyelocytic leukemia in long-term remission after the AIDA protocol.
Pellicori P; Calicchia A; Lococo F; Cimino G; Torromeo C
Congest Heart Fail; 2012; 18(4):217-21. PubMed ID: 22809260
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
17. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H; Nielsen G
Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
[TBL] [Abstract][Full Text] [Related]
18. A longitudinal study of cardiac function in children with cancer over 40 months.
Li CK; Sung RY; Kwok KL; Leung TF; Shing MM; Chik KW; Yu CW; Yam MC; Yuen PM
Pediatr Hematol Oncol; 2000; 17(1):77-83. PubMed ID: 10689717
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
20. Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model.
Hayward R; Lien CY; Jensen BT; Hydock DS; Schneider CM
Pediatr Blood Cancer; 2012 Jul; 59(1):149-54. PubMed ID: 22052855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]